Data on Omeros' Omidria - Analyst Blog

By
A A A

Omeros Corporation ( OMER ) is looking to get its pipeline candidate, Omidria (OMS302), approved in the U.S. and EU for the treatment of patients undergoing intraocular lens replacement (ILR) surgery. Omidria is Omeros' proprietary pharmacosurgery product.

Omeros recently reported analyses of phase III data on Omidria at the Annual American Academy of Ophthalmology (AAO).

Data revealed that Omidria reduced the occurrence of intraoperative pupil constriction (miosis). It was demonstrated that pupil constriction of at least 3 millimeters was common in control patients while constriction greater than 1 millimeter was uncommon in Omidria treated patients.

We remind investors that Omidria was filed for approval in the U.S. and EU in Jul and Sep 2013, respectively. In Oct 2013, the new drug application for Omidria was accepted for review by the Food and Drug Administration. The marketing authorization application in the EU was validated by the European authorities in the same month. Omeros expects to launch Omidria in the second half of 2014, assuming approval.

Omeros expects to commence an expansion study by the end of the year to include a subset of ILR patients who have a history of using alpha adrenergic antagonists, such as, Flomax (tamsulosin), indicated for intraoperative floppy iris syndrome (IFIS).

We are encouraged by Omeros' progress on Omidria. The ophthalmology market is currently dominated by players like Allergan Inc. ( AGN ) and Novartis ( NVS ).

Omeros, a biopharmaceutical company, at present carries a Zacks Rank #3 (Hold). Biopharma stocks such as Actelion Ltd. ( ALIOF ), carrying a Zacks Rank #1 (Strong Buy), currently look more attractive.



ALLERGAN INC (AGN): Free Stock Analysis Report

ACTELION LTD (ALIOF): Get Free Report

NOVARTIS AG-ADR (NVS): Free Stock Analysis Report

OMEROS CORP (OMER): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: AGN , ALIOF , NVS , OMER

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

67%
100%
100%

Most Active by Volume

48,099,947
  • $16.09 ▲ 0.50%
40,277,806
  • $102.50 ▲ 0.24%
40,236,499
  • $19.57 ▲ 2.35%
31,092,510
  • $49.75 ▲ 0.65%
30,795,218
  • $34.92 ▲ 0.78%
29,910,855
  • $3.63 ▲ 0.83%
24,019,154
  • $13.06 ▼ 0.38%
23,753,906
  • $74.82 ▲ 1.31%
As of 8/29/2014, 04:04 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com